
Novo Nordisk plans to initiate a new phase IIIa trial program against obesity with the firm's molecule semaglutide, according to a press release on Wednesday afternoon.
Notably, the trial revolves around oral semaglutide.
Already a subscriber? Log in.
Read the whole article
Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
- Access all locked articles
- Receive our daily newsletters
- Access our app